Podcasts about Scorpion

L''Horoscope du Samedi 22 Novembre

L''Horoscope du Samedi 22 Novembre

L''Horoscope du Samedi 22 Novembre

John Murray & Ali Bruce-Ball are joined by Jonathan Agnew to discuss commentating on cricket. He talks about his journey from lorry driver to broadcaster. Aggers reveals how much prep he does and his commentary top tips. And suggestions always welcome for our Great Glossary of Football Commentary and unintended pub names from commentary - WhatsApp voicenotes to 08000 289 369 & emails to TCV@bbc.co.uk03:55 Jonathan Agnew joins the pod 08:45 From archery & dressage to Ben Stokes in 2019 12:45 What prep Aggers does for cricket? 18:00 From lorry driver to broadcaster 23:10 Aggers' Ashes memories down under 32:00 How to follow the Ashes on the BBC 35:25 Unintended pub names 39:30 Jonathan's favourite commentators' view 45:25 Great Glossary of Football Commentary 55:30 Jonathan on commentating on a replay!5 Live / BBC Sounds Premier League commentaries: Sat 1500 Liverpool v Forest, Sat 1500 Fulham v Sunderland on Sports Extra, Sat 1730 Newcastle v Man City, Sun 1400 Leeds v Aston Villa, Sun 1630 Arsenal v Tottenham, Tue 2000 Chelsea v Barcelona, Tue 2000 Man City v Bayer Leverkusen on Sports Extra, Wed 2000 Arsenal v Bayern Munich, Wed 2000 PSG v Tottenham on Sports Extra,Glossary so far (in alphabetical order):DIVISION ONE Bosman, Couldn't sort their feet out, Cruyff Turn, Dead-ball specialist, Fox in the box, Giving the goalkeeper the eyes, Head tennis, Hibs it, In a good moment, Johnny on the spot, The Maradona, Olimpico, Onion bag, Panenka, Rabona, Scorpion kick, Spursy, Tiki-taka, Where the kookaburra sleeps, Where the owl sleeps, Where the spiders sleep.DIVISION TWO Ball stays hit, Business end, Came down with snow on it, Catching practice, Cauldron atmosphere Coat is on a shoogly peg, Come back to haunt them, Corridor of uncertainty, Easy tap-in, Daisy-cutter, First cab off the rank, Good leave, Has that in his locker, High wide and not very handsome, Howler, Leading the line, Nutmeg, One for the cameras, One for the purists, Played us off the park, Purple patch, Put their laces through it, Rolls Royce, Root and branch review, Row Z, Screamer, Seats on the plane, Show across the bows, Stramash, Taking one for the team, That's great… (football), Thunderous strike.UNSORTED 2-0 is a dangerous score, After you Claude, All-Premier League affair, Aplomb, Bag/box of tricks, Brace, Brandished, Bread and butter, Breaking the deadlock, Bundled over the line, Champions elect / champions apparent, Clinical finish, Commentator's curse, Coupon buster, Cultured/Educated left foot, Denied by the woodwork, Draught excluder, Elimination line, Fellow countryman, Foot race, Formerly of this parish, Free hit, Goalkeepers' Union, Goalmouth scramble, Good touch for a big man, Honeymoon Period, In and around, In the shop window, Keeping ball under their spell, Keystone Cops defending, Languishing, Loitering with intent, Marching orders, Nestle in the bottom corner, Numbered derbies, Opposite number, Park the bus, PK for penalty-kick, Postage stamp, Put it in the mixer, Rasping shot, Red wine not white wine, Relegation six-pointer, Rooted at the bottom, Route One, Roy of the Rovers stuff, Sending the goalkeeper the wrong way, Shooting boots, Sleeping giants, Slide rule pass, Small matter of, Spiders web, Stayed hit, Steepling, Stinging the palms, Stonewall penalty, Straight off the training ground, Taking one for the team, Team that likes to play football, Throw their cap on it, Thruppenny bit head / 50p head, Towering header, Two good feet, Turning into a basketball match, Turning into a cricket score, Usher/Shepherd the ball out of play, Walking a disciplinary tightrope, Wand of a left foot, We've got a cup tie on our hands, Winger in their pocket, Wrap foot around it, Your De Bruynes, your Gundogans etc.

L''Horoscope du Vendredi 21 Novembre

Bienvenue dans Les Étoilés, votre dose astro du matin. Aujourd'hui, on vous donne juste une mise en bouche : quelques mots ! Bélier : décompressez, ça change tout.Taureau : journée fluide, zéro pression.Cancer : voyage ? Comparez avant.Vierge : focus total.Balance : amitiés > amour.Sagittaire : petites pauses, grand effet.Capricorne : attention dispersion.Verseau : avancez, même doucement.Poissons : clarifiez avant d'agir.Et maintenant, place aux trois signes qui brillent — les Étoilés du jour :Gémeaux : vibe charme + options.Lion : douceur, chaleur, attention.Scorpion : puissance, clarté, élan.Pour le détail, les nuances, les messages cachés et les énergies subtiles du jour… rendez-vous dans l'épisode complet

L''Horoscope du Vendredi 21 Novembre

L''Horoscope du Vendredi 21 Novembre

Dr. Linda Duska and Dr. Kathleen Moore discuss key studies in the evolving controversy over radical upfront surgery versus neoadjuvant chemotherapy in advanced ovarian cancer. TRANSCRIPT Dr. Linda Duska: Hello, and welcome to the ASCO Daily News Podcast. I am your guest host, Dr. Linda Duska. I am a professor of obstetrics and gynecology at the University of Virginia School of Medicine.  On today's episode, we will explore the management of advanced ovarian cancer, specifically with respect to a question that has really stirred some controversy over time, going all the way back more than 20 years: Should we be doing radical upfront surgery in advanced ovarian cancer, or should we be doing neoadjuvant chemotherapy? So, there was a lot of hype about the TRUST study, also called ENGOT ov33/AGO-OVAR OP7, a Phase 3 randomized study that compares upfront surgery with neoadjuvant chemotherapy followed by interval surgery. So, I want to talk about that study today. And joining me for the discussion is Dr. Kathleen Moore, a professor also of obstetrics and gynecology at the University of Oklahoma and the deputy director of the Stephenson Cancer Center, also at the University of Oklahoma Health Sciences.  Dr. Moore, it is so great to be speaking with you today. Thanks for doing this. Dr. Kathleen Moore: Yeah, it's fun to be here. This is going to be fun. Dr. Linda Duska: FYI for our listeners, both of our full disclosures are available in the transcript of this episode.  So let's just jump right in. We already alluded to the fact that the TRUST study addresses a question we have been grappling with in our field. Here's the thing, we have four prior randomized trials on this exact same topic. So, share with me why we needed another one and what maybe was different about this one? Dr. Kathleen Moore: That is, I think, the key question. So we have to level-set kind of our history. Let's start with, why is this even a question? Like, why are we even talking about this today? When we are taking care of a patient with newly diagnosed ovarian cancer, the aim of surgery in advanced ovarian cancer ideally is to prolong a patient's likelihood of disease-free survival, or if you want to use the term "remission," you can use the term "remission." And I think we can all agree that our objective is to improve overall survival in a way that also does not compromise her quality of life through surgical complications, which can have a big effect. The standard for many decades, certainly my entire career, which is now over 20 years, has been to pursue what we call primary cytoreductive surgery, meaning you get a diagnosis and we go right to the operating room with a goal of achieving what we call "no gross residual." That is very different – in the olden days, you would say "optimal" and get down to some predefined small amount of tumor. Now, the goal is you remove everything you can see.  The alternative strategy to that is neoadjuvant chemotherapy followed by interval cytoreductive surgery, and that has been the, quote-unquote, "safer" route because you chemically cytoreduce the cancer, and so, the resulting surgery, I will tell you, is not necessarily easy at all. It can still be very radical surgeries, but they tend to be less radical, less need for bowel resections, splenectomy, radical procedures, and in a short-term look, would be considered safer from a postoperative consideration. Dr. Linda Duska: Well, and also maybe more likely to be successful, right? Because there's less disease, maybe, theoretically. Dr. Kathleen Moore: More likely to be successful in getting to no gross residual. Dr. Linda Duska: Right. Yeah, exactly. Dr. Kathleen Moore: I agree with that. And so, so if the end game, regardless of timing, is you get to no gross residual and you help a patient and there's no difference in overall survival, then it's a no-brainer. We would not be having this conversation. But there remains a question around, while it may be more likely to get to no gross residual, it may be, and I think we can all agree, a less radical, safer surgery, do you lose survival in the long term by this approach? This has become an increasing concern because of the increase in rates of use of neoadjuvant, not only in this country, but abroad. And so, you mentioned the four prior studies. We will not be able to go through them completely. Dr. Linda Duska: Let's talk about the two modern ones, the two from 2020 because neither one of them showed a difference in overall survival, which I think we can agree is, at the end of the day, yes, PFS would be great, but OS is what we're looking for. Dr. Kathleen Moore: OS is definitely what we're looking for. I do think a marked improvement in PFS, like a real prolongation in disease-free survival, for me would be also enough. A modest improvement does not really cut it, but if you are really, really prolonging PFS, you should see that-  Dr. Linda Duska: -manifest in OS. Dr. Kathleen Moore: Yeah, yeah. Okay. So let's talk about the two modern ones. The older ones are EORTC and CHORUS, which I think we've talked about. The two more modern ones are SCORPION and JCOG0602. So, SCORPION was interesting. SCORPION was a very small study, though. So one could say it's underpowered. 170 patients. And they looked at only patients that were incredibly high risk. So, they had to have a Fagotti score, I believe, of over 9, but they were not looking at just low volume disease. Like, those patients were not enrolled in SCORPION. It was patients where you really were questioning, "Should I go to the OR or should I do neoadjuvant? Like, what's the better thing?" It is easy when it's low volume. You're like, "We're going." These were the patients who were like, "Hm, you know, what should I do?" High volume. Patients were young, about 55. The criticism of the older studies, there are many criticisms, but one of them is that, the criticism that is lobbied is that they did not really try. Whatever surgery you got, they did not really try with median operative times of 180 minutes for primary cytoreduction, 120 for neoadjuvant. Like, you and I both know, if you're in a big primary debulking, you're there all day. It's 6 hours. Dr. Linda Duska: Right, and there was no quality control for those studies, either. Dr. Kathleen Moore: No quality control. So, SCORPION, they went 451-minute median for surgery. Like, they really went for it versus four hours and then 253 for the interval, 4 hours. They really went for it on both arms. Complete gross resection was achieved in 50% of the primary cytoreduced. So even though they went for it with these very long surgeries, they only got to the goal half the time. It was almost 80% in the interval group. So they were more successful there. And there was absolutely no difference in PFS or OS. They were right about 15 months PFS, right about 40 months OS.  JCOG0602, of course, done in Japan, a big study, 300 patients, a little bit older population. Surprisingly more stage IV disease in this study than were in SCORPION. SCORPION did not have a lot of stage IV, despite being very bulky tumors. So a third of patients were stage IV. They also had relatively shorter operative times, I would say, 240 minutes for primary, 302 for interval. So still kind of short. Complete gross resection was not achieved very often. 30% of primary cytoreduction. That is not acceptable. Dr. Linda Duska: Well, so let's talk about TRUST. What was different about TRUST? Why was this an important study for us to see? Dr. Kathleen Moore: So the criticism of all of these, and I am not trying to throw shade at anyone, but the criticism of all of these is if you are putting surgery to the test, you are putting the surgeon to the test. And you are assuming that all surgeons are trained equally and are willing to do what it takes to get someone to no gross residual. Dr. Linda Duska: And are in a center that can support the post-op care for those patients. Dr. Kathleen Moore: Which can be ICU care, prolonged time. Absolutely. So when you just open these broadly, you're assuming everyone has the surgical skills and is comfortable doing that and has backup. Everybody has an ICU. Everyone has a blood bank, and you are willing to do that. And that assumption could be wrong. And so what TRUST said is, "Okay, we are only going to open this at centers that have shown they can achieve a certain level of primary cytoreduction to no gross residual disease." And so there was quality criteria. It was based on – it was mostly a European study – so ESGO criteria were used to only allow certified centers to participate. They had to have a surgical volume of over 36 cytoreductive surgeries per year. So you could not be a low volume surgeon. Your complete resection rates that were reported had to be greater than 50% in the upfront setting. I told you on the JCOG, it was 30%. Dr. Linda Duska: Right. So these were the best of the best. This was the best possible surgical situation you could put these patients in, right? Dr. Kathleen Moore: Absolutely. And you support all the things so you could mitigate postoperative complications as well. Dr. Linda Duska: So we are asking the question now again in the ideal situation, right? Dr. Kathleen Moore: Right. Dr. Linda Duska: Which, we can talk about, may or may not be generalizable to real life, but that's a separate issue because we certainly don't have those conditions everywhere where people get cared for with ovarian cancer. But how would you interpret the results of this study? Did it show us anything different? Dr. Kathleen Moore: I am going to say how we should interpret it and then what I am thinking about. It is a negative study. It was designed to show improvement in overall survival in these ideal settings in patients with FIGO stage IIIB and C, they excluded A, these low volume tumors that should absolutely be getting surgery. So FIGO stage IIIB and C and IVA and B that were fit enough to undergo radical surgery randomized to primary cytoreduction or neoadjuvant with interval, and were all given the correct chemo. Dr. Linda Duska: And they were allowed bevacizumab and PARP, also. They could have bevacizumab and PARP. Dr. Kathleen Moore: They were allowed bevacizumab and PARP. Not many of them got PARP, but it was distributed equally, so that would not be a confounder. And so that was important. Overall survival is the endpoint. It was a big study. You know, it was almost 600 patients. So appropriately powered. So let's look at what they reported. When they looked at the patients who were enrolled, this is a large study, almost 600 patients, 345 in the primary cytoreductive arm and 343 in the neoadjuvant arm. Complete resection in these patients was 70% in the primary cytoreductive arm and 85% in the neoadjuvant arm. So in both arms, it was very high. So your selection of site and surgeon worked. You got people to their optimal outcome. So that is very different than any other study that has been reported to date. But what we saw when we looked at overall survival was no statistical difference. The median was, and I know we do not like to talk about medians, but the median in the primary cytoreductive arm was 54 months versus 48 months in the neoadjuvant arm with a hazard ratio of 0.89 and, of course, the confidence interval crossed one. So this is not statistically significant. And that was the primary endpoint. Dr. Linda Duska: I know you are getting to this. They did look at PFS, and that was statistically significant, but to your point about what are we looking for for a reasonable PFS difference? It was about two months difference. When I think about this study, and I know you are coming to this, what I thought was most interesting about this trial, besides the fact that the OS, the primary endpoint was negative, was the subgroup analyses that they did. And, of course, these are hypothesis-generating only. But if you look at, for example, specifically only the stage III group, that group did seem to potentially, again, hypothesis generating, but they did seem to benefit from upfront surgery.  And then one other thing that I want to touch on before we run out of time is, do we think it matters if the patient is BRCA germline positive? Do we think it matters if there is something in particular about that patient from a biomarker standpoint that is different? I am hopeful that more data will be coming out of this study that will help inform this. Of course, unpowered, hypothesis-generating only, but it's just really interesting. What do you think of their subset analysis? Dr. Kathleen Moore: Yeah, I think the subsets are what we are going to be talking about, but we have to emphasize that this was a negative trial as designed. Dr. Linda Duska: Absolutely. Yes. Dr. Kathleen Moore: So we cannot be apologists and be like, "But this or that." It was a negative trial as designed. Now, I am a human and a clinician, and I want what is best for my patients. So I am going to, like, go down the path of subset analyses. So if you look at the stage III tumors that got complete cytoreduction, which was 70% of the cases, your PFS was almost 28 months versus 21.8 months. Dr. Linda Duska: Yes, it becomes more significant. Dr. Kathleen Moore: Yeah, that hazard ratio is 0.69. Again, it is a subset. So even though the P value here is statistically significant, it actually should not have a P value because it is an exploratory analysis. So we have to be very careful. But the hazard ratio is 0.69. So the hypothesis is in this setting, if you're stage III and you go for it and you get someone to no gross residual versus an interval cytoreduction, you could potentially have a 31% reduction in the rate of progression for that patient who got primary cytoreduction. And you see a similar trend in the stage III patients, if you look at overall survival, although the post-progression survival is so long, it's a little bit narrow of a margin.  But I do think there are some nuggets here that, one of our colleagues who is really one of the experts in surgical studies, Dr. Mario Leitao, posted this on X, and I think it really resonated after this because we were all saying, "But what about the subsets?" He is like, "It's a negative study." But at the end of the day, you are going to sit with your patient. The patient should be seen by a GYN oncologist or surgical oncologist with specialty in cytoreduction and a medical oncologist, you know, if that person does not give chemo, and the decision should be made about what to do for that individual patient in that setting. Dr. Linda Duska: Agreed. And along those lines, if you look carefully at their data, the patients who had an upfront cytoreduction had almost twice the risk of having a stoma than the patients who had an interval cytoreduction. And they also had a higher risk of needing to have a bowel resection. The numbers were small, but still, when you look at the surgical complications, as you've already said, they're higher in the upfront group than they are in the interval group. That needs to be taken into account as well when counseling a patient, right? When you have a patient in front of you who says to you, "Dr. Moore, you can take out whatever you want, but whatever you do, don't make me a bag." As long as the patient understands what that means and what they're asking us to do, I think that we need to think about that. Dr. Kathleen Moore: I think that is a great point. And I have definitely seen in our practice, patients who say, "I absolutely would not want an ostomy. It's a nonstarter for me." And we do make different decisions. And you have to just say, "That's the decision we've made," and you kind of move on, and you can't look back and say, "Well, I wish I would have, could have, should have done something else." That is what the patient wants. Ultimately, that patient, her family, autonomous beings, they need to be fully counseled, and you need to counsel that patient as to the site that you are in, her volume of disease, and what you think you can achieve. In my opinion, a patient with stage III cancer who you have the site and the capabilities to get to no gross residual should go to the OR first. That is what I believe. I do not anymore think that for stage IV. I think that this is pretty convincing to me that that is probably a harmful thing. However, I want you to react to this. I think I am going to be a little unpopular in saying this, but for me, one of the biggest take-homes from TRUST was that whether or not, and we can talk about the subsets and the stage III looked better, and I think it did, but both groups did really well. Like, really well. And these were patients with large volume disease. This was not cherry-picked small volume stage IIIs that you could have done an optimal just by doing a hysterectomy. You know, these were patients that needed radical surgery. And both did well. And so what it speaks to me is that anytime you are going to operate on someone with ovary, whether it be frontline, whether it be a primary or interval, you need a high-volume surgeon. That is what I think this means to me. Like, I would want high volume surgeon at a center that could do these surgeries, getting that patient, my family member, me, to no gross residual. That is important. And you and I are both in training centers. I think we ought to take a really strong look at, are we preparing people to do the surgeries that are necessary to get someone to no gross residual 70% and 85% of the time? Dr. Linda Duska: We are going to run out of time, but I want to address that and ask you a provocative question. So, I completely agree with what you said, that surgery is important. But I also think one of the reasons these patients in this study did so well is because all of the incredible new therapies that we have for patients. Because OS is not just about surgery. It is about surgery, but it is also about all of the amazing new therapies we have that you and others have helped us to get through clinical research. And so, how much of that do you think, like, for example, if you look at the PFS and OS rates from CHORUS and EORTC, I get it that they're, that they're not the same. It's different patients, different populations, can't do cross-trial comparisons. But the OS, as you said, in this study was 54 months and 48 months, which is, compared to 2010, we're doing much, much better. It is not just the surgery, it is also all the amazing treatment options we have for these patients, including PARP, including MIRV, including lots of other new therapies. How do you fit that into thinking about all of this? Dr. Kathleen Moore: I do think we are seeing, and we know this just from epidemiologic data that the prevalence of ovarian cancer in many of the countries where the study was done is increasing, despite a decrease in incidence. And why is that? Because people are living longer. Dr. Linda Duska: People are living longer, yeah. Dr. Kathleen Moore: Which is phenomenal. That is what we want. And we do have, I think, better supportive care now. PARP inhibitors in the frontline, which not many of these patients had. Now some of them, this is mainly in Europe, will have gotten them in the first maintenance setting, and I do think that impacts outcome. We do not have that data yet, you know, to kind of see what, I would be really interested to see. We do not do this well because in ovarian cancer, post-progression survival can be so long, we do not do well of tracking what people get when they come off a clinical trial to see how that could impact – you know, how many of them got another surgery? How many of them got a PARP? I think this group probably missed the ADC wave for the most part, because this, mirvetuximab is just very recently available in Europe. Dr. Linda Duska: Unless they were on trial. Dr. Kathleen Moore: Unless they were on trial. But I mean, I think we will have to see. 600 patients, I would bet a lot of them missed the ADC wave. So, I do not know that we can say we know what drove these phenomenal – these are some of the best curves we've seen outside of BRCA. And then coming back to your point about the BRCA population here, that is a really critical question that I do not know that we're ever going to answer. There have been hypotheses around a tumor that is driven by BRCA, if you surgically cytoreduced it, and then chemically cytoreduced it with chemo, and so you're starting PARP with nothing visible and likely still homogeneous clones. Is that the group we cured? And then if you give chemo first before surgery, it allows more rapid development of heterogeneity and more clonal evolution that those are patients who are less likely to be cured, even if they do get cytoreduced to nothing at interval with use of PARP inhibitor in the front line. That is a question that many have brought up as something we would like to understand better. Like, if you are BRCA, should you always just go for it or not? I do not know that we're ever going to really get to that. We are trying to look at some of the other studies and just see if you got neoadjuvant and you had BRCA, was anyone cured? I think that is a question on SOLO1 I would like to know the answer to, and I don't yet, that may help us get to that. But that's sort of something we do think about. You should have a fair number of them in TRUST. It wasn't a stratification factor, as I remember. Dr. Linda Duska: No, it wasn't. They stratified by center, age, and ECOG status Dr. Kathleen Moore: So you would hope with randomization that you would have an equal number in each arm. And they may be able to pull that out and do a very exploratory look. But I would be interested to see just completely hypothesis-generating what this looks like for the patients with BRCA, and I hope that they will present that. I know they're busy at work. They have translational work. They have a lot pending with TRUST. It's an incredibly rich resource that I think is going to teach us a lot, and I am excited to see what they do next. Dr. Linda Duska: So, outside of TRUST, we are out of time. I just want to give you a moment if there were any other messages that you want to share with our listeners before we wrap up. Dr. Kathleen Moore: It's an exciting time to be in GYN oncology. For so long, it was just chemo, and then the PARP inhibitors nudged us along quite a bit. We did move more patients, I believe, to the cure fraction. When we ultimately see OS, I think we'll be able to say that definitively, and that is exciting. But, you know, that is the minority of our patients. And while HRD positive benefits tremendously from PARP, I am not as sure we've moved as many to the cure fraction. Time will tell. But 50% of our patients have these tumors that are less HRD. They have a worse prognosis. I think we can say that and recur more quickly. And so the advent of these antibody-drug conjugates, and we could name 20 of them in development in GYN right now, targeting tumor-associated antigens because we're not really driven by mutations other than BRCA. We do not have a lot of things to come after. We're not lung cancer. We are not breast cancer. But we do have a lot of proteins on the surface of our cancers, and we are finally able to leverage that with some very active regimens. And we're in the early phases, I would say, of really understanding how best to use those, how best to position them, and which one to select for whom in a setting where there is going to be obvious overlap of the targets. So we're going to be really working this problem. It is a good problem. A lot of drugs that work pretty well. How do you individualize for a patient, the patient in front of you with three different markers? How do you optimize it? Where do you put them to really prolong survival? And then we finally have cell surface. We saw at ASCO, CDK2 come into play here for the first time, we've got a cell cycle inhibitor. We've been working on WEE1 and ATR for a long time. CDK2s may hit. Response rates were respectable in a resistant population that was cyclin E overexpressing. We've been working on that biomarker for a long time with a toxicity profile that was surprisingly clean, which I like to see for our patients. So that is a different platform. I think we have got bispecifics on the rise. So there is a pipeline of things behind the ADCs, which is important because we need more than one thing, that makes me feel like in the future, I am probably not going to be using doxil ever for platinum-resistant disease. So, I am going to be excited to retire some of those things. We will say, "Remember when we used to use doxil for platinum-resistant disease?" Dr. Linda Duska: I will be retired by then, but thanks for that thought. Dr. Kathleen Moore: I will remind you. Dr. Linda Duska: You are right. It is such an incredibly exciting time to be taking care of ovarian cancer patients with all the opportunities.  And I want to thank you for sharing your valuable insights with us on this podcast today and for your great work to advance care for patients with GYN cancers. Dr. Kathleen Moore: Likewise. Thanks for having me. Dr. Linda Duska: And thank you to our listeners for your time today. You will find links to the TRUST study and other studies discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Linda Duska  @Lduska Dr. Kathleen Moore Follow ASCO on social media:     @ASCO on X (formerly Twitter) ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures of Potential Conflicts of Interest:    Dr. Linda Duska:   Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma  Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics  Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn  Dr. Kathleen Moore: Leadership: GOG Partners, NRG Ovarian Committee Chair Honoraria: Astellas Medivation, Clearity Foundation, IDEOlogy Health, Medscape, Great Debates and Updates, OncLive/MJH Life Sciences, MD Outlook, Curio Science, Plexus, University of Florida, University of Arkansas for Medical Sciences, Congress Chanel, BIOPHARM, CEA/CCO, Physician Education Resource (PER), Research to Practice, Med Learning Group, Peerview, Peerview, PeerVoice, CME Outfitters, Virtual Incision Consulting/Advisory Role: Genentech/Roche, Immunogen, AstraZeneca, Merck, Eisai, Verastem/Pharmacyclics, AADi, Caris Life Sciences, Iovance Biotherapeutics, Janssen Oncology, Regeneron, zentalis, Daiichi Sankyo Europe GmbH, BioNTech SE, Immunocore, Seagen, Takeda Science Foundation, Zymeworks, Profound Bio, ADC Therapeutics, Third Arc, Loxo/Lilly, Bristol Myers Squibb Foundation, Tango Therapeutics, Abbvie, T Knife, F Hoffman La Roche, Tubulis GmbH, Clovis Oncology, Kivu, Genmab/Seagen, Kivu, Genmab/Seagen, Whitehawk, OnCusp Therapeutics, Natera, BeiGene, Karyopharm Therapeutics, Day One Biopharmaceuticals, Debiopharm Group, Foundation Medicine, Novocure Research Funding (Inst.): Mersana, GSK/Tesaro, Duality Biologics, Mersana, GSK/Tesaro, Duality Biologics, Merck, Regeneron, Verasatem, AstraZeneca, Immunogen, Daiichi Sankyo/Lilly, Immunocore, Torl Biotherapeutics, Allarity Therapeutics, IDEAYA Biosciences, Zymeworks, Schrodinger Other Relationship (Inst.): GOG Partners

L''Horoscope du Jeudi 20 Novembre

L''Horoscope du Jeudi 20 Novembre

En este episodio nos adentramos en las sombras para hablar de los ninjas más míticos de la historia del videojuego. Desde los maestros del sigilo de Tenchu, pasando por la locura arcade de Shinobi, la brutalidad de Ninja Gaiden, el universo eterno de las Tortugas Ninja, y los legendarios Scorpion y Sub-Zero de Mortal Kombat. Un viaje lleno de nostalgia, humor y recuerdos gamers de nuestra infancia y adolescencia. ️ Si creciste con una consola entre las manos, este episodio te va a tocar la fibra. TÓPICOS DEL EPISODIO (sin spoilers) La influencia de los juegos ninja en la cultura pop Anécdotas reales que vivíamos como auténticos ninjas en los 90 Qué títulos definieron el género y por qué siguen siendo inolvidables Debate: ¿Cuál es el ninja definitivo de los videojuegos? NO TE LO PIERDAS SI TE GUSTA: ✔️ Tenchu ✔️ Sega Mega Drive y Arcades ✔️ Tortugas Ninja ✔️ Mortal Kombat ✔️ Retro gaming y nostalgia gamer de los 90 y 2000 ¿QUIÉNES SOMOS? ️ Gluten Pollo Podcast — Humor, cultura pop y videojuegos sin postureos. Cada semana un viaje nostálgico desde Asturias al mundo entero.

L''Horoscope du Jeudi 20 Novembre

Your Scorpio Superpower is a Deep Knowing of  Truth.Journeying around the zodiac with each new moon offers  specific guidance for  life and Soul direction.As a fixed sign, Scorpio symbolizes the conserving of emotional energy. This sign specializes in searching for the depth in whatever is not obvious.Looking inward and gaining an understanding of what is meaningful and worthwhile is essential. In terms of merging in an intimate way, there's the need to reach out and move toward others. This connection is most comfortably done on a one to one emotional level.Scorpio depicts the archetypes of the Scorpion and the Eagle, as well as being described in mythical literature as the “Phoenix bird”.  Each symbol offers a meaning that presents a level of inner awareness and consciousness.This sign is associated with the subject of “depth/archetypal psychology”.  The root or archetypal theme is about penetrating into the inner realm of the “Psyche”/Soul.  It requires a willingness to use the intuitive, emotional feeling and sensing capacity to navigate through life experiences. Scorpio is not well understood because it operates, in great part, from the psycho-spiritual realm.  The need to perceive the inner workings through the emotions, and soul experiences requires reference to the non-ordinary states of being.Scorpio is feminine water sign, meaning that it acts from a receptive activation. Most interesting though. is its guidance and rulership  as well as co-rulership with Mars and Pluto.  As 2026 moves forward into our collective consciousness,  this  watery, intuitive Scorpio connection is preparing all who are willing, to undertake a personal journey through this empowering lunar cycle.  One of the keys to using Scorpio energy is being willing to investigate yourself from the inside out.  Move into deep exploration of what feels beautiful, artful, creative and what aspects of your life you really value.Let those creative expressions come forth.Give yourself major self care through rest and relaxation.This Lunar cycle provides deep self understanding using the sign of Scorpio as an inner “Mirror”.  Decide now to face what is not You, as you Stand and Face the Intention to plant and grow something new and worthy of the new you. Let's have an Astrology Conversation. I look forward to seeing you. Now is the time.https://www.soulsoundinsights.com/light-reading.htmlhttps://www.soulsoundinsights.com/music-musings-meditation.htmlI am proud to announce my new offering as a Certified Creative Depth Coach. As a Creative Depth Coach, I provide guidance, support and soul insights on how to discover, explore and navigate your life by recognizing your magnificent "Creative Genius". Some of my modalities and Soul tools are "Art as Process" EFT Tapping, Sound and Music for Inner Journeying , using the wisdom of Astrology, Tarot, Oracle and Numerology. l Enjoy Full Moon Lunar Eclipse in Taurus Drumming Video:https://vimeo.com/769123538/b344b2b541"Calling the Wild", Original Music by MaeRuth McCants

À l’approche des Fêtes, Patrick, Tatiana et Isabelle explorent un phénomène étonnant : la location de « chum » pour esquiver les questions gênantes en famille. Patrick met en garde contre les dérives potentielles de cette industrie inattendue, tandis qu’Isabelle admet que la tentation devient réelle face à la pression sociale du célibat. On plonge aussi dans l’histoire fascinante de Hello Kitty, née d’un dessin rejeté 47 fois et devenue un phénomène mondial. Laurie Lévesque, astrologue, invite à profiter de la nouvelle lune en Scorpion pour réfléchir, libérer les blocages et transformer tensions et inconforts en opportunités. Un épisode qui mêle humour, persévérance et introspection pour bien finir l'année.Voir https://www.cogecomedia.com/vie-privee pour notre politique de vie privée

L''Horoscope du Mercredi 19 Novembre

L''Horoscope du Mercredi 19 Novembre

L''Horoscope du Mercredi 19 Novembre

Accédez gratuitement au support écrit associé à l'épisode: découvrez la newsletter

L''Horoscope du Mardi 18 Novembre

L''Horoscope du Mardi 18 Novembre

L''Horoscope du Mardi 18 Novembre

✨tu peux m'envoyer un message ici ✨Salut à toi ✨Et la voilà, cette nouvelle Lune qui vient se démarquer des dernières lunaisons. Elle est toute en profondeur et en authenticité, elle nous allège et nous ouvre des horizons que nous aurions bien pu oublier dans cette énergie de fin de cycle qui nous accompagne depuis plusieurs mois maintenant.

L''Horoscope du Lundi 17 Novembre

L''Horoscope du Lundi 17 Novembre

L''Horoscope du Lundi 17 Novembre

Scorpion Milk's Mat McNerny joins us today in the second part of our chat to discuss the most clairvoyant of odd movies from the 80s, 'War of the Worlds: Next Century'. Mat's latest album is called 'Slime of the Times' and I can not stop listening to it. So why not ask him to come onto a show about horror movies and combine my two passions. DOUBLE BOOM!

L''Horoscope du Dimanche 16 Novembre

L''Horoscope du Dimanche 16 Novembre

L''Horoscope du Dimanche 16 Novembre

In honor of 420, its time to look at some of the weirdest, and wackiest toys ever designed. You really have to wonder, what were they on when coming up with some of this stuff. From poorly thought out labels to accidental nightmare fuel, child endangerment and even a pre-cursor to Siri - combined with, water? Then it's another edition of The Team from the wonderful world of TMNT - but ONLY the Turtle variants. And the choices are not as simple as you might think! Support the show: http://patreon.com/toypowerpodcastSee omnystudio.com/listener for privacy information.

This November 2025 Scorpio New Moon guided meditation is your invitation to slow down, breathe deeper, and step into a calm space where manifesting becomes natural. Scorpio's New Moon energy helps you release emotional weight, reconnect with yourself, and set new intentions for the cycle ahead.In this journey, we move through the Scorpion, Phoenix, and Eagle phases — letting go of what feels heavy, rising renewed, and seeing life from a higher, clearer view. The theta binaural beats support your nervous system so you can relax, reset your energy, and connect with the intentions you want to bring forward.If you're ready to start the new lunar cycle feeling steady and focused, settle in and press play.If this meditation supports you, join me inside the 28-Day Lunar Cycle Reset — a month-long experience of meditations, reflections, and lunar practices designed to help you stay intuitive, balanced, and connected through each phase.

L''Horoscope du Samedi 15 Novembre

L''Horoscope du Samedi 15 Novembre

L''Horoscope du Samedi 15 Novembre

Scorpion, vous vivrez des débats respectueux

John Murray, Ali Bruce-Ball & Conor McNamara talk football, travel & language after Cristiano Ronaldo sees red as Republic of Ireland beat Portugal, and England beat Serbia. What about the ‘mind-altering' shoes some of the England players are wearing? There's a European theme to Clash of the Commentators. And suggestions always welcome for our Great Glossary of Football Commentary and unintended pub names from football commentary - WhatsApp voicenotes to 08000 289 369 & emails to TCV@bbc.co.uk00:40 Conor fresh from Ireland-Portugal 04:40 Takeaways from England-Serbia 06:05 Mind-altering shoes & commentary attire 16:05 5 Live commentaries this weekend 18:00 John prepares for trip to Albania 24:55 Unintended (and intended) pub names 33:15 Clash of the Commentators 41:45 Great Glossary of Football Commentary 52:55 Magazine memories5 Live / BBC Sounds Premier League commentaries: Fri 1945 Slovakia v Northern Ireland on Sports Extra, Sat 1330 Man City v Man Utd in WSL on Sports Extra, Sat 1700 Liechtenstein v Wales on Sports Extra, Sat 1945 Greece v Scotland on 5 Live, Sun 1200 Liverpool v Chelsea in WSL on Sports Extra, Sun 1200 Brighton v Leicester in WSL on Sports Extra 2, Sun 1430 Tottenham v Arsenal in WSL on 5 Live, Sun 1700 Albania v England on 5 Live, Mon 1945 Northern Ireland v Luxembourg on Sports Extra, Tue 1945 Scotland v Denmark on 5 Live, Tue 1945 Wales v North Macedonia on Sports Extra, Wed 2000 Arsenal v Real Madrid in UWCL on 5 Live, Thu 2000 Chelsea v Barcelona in UWCL on 5 Live.Glossary so far (in alphabetical order):DIVISION ONE Bosman, Cruyff Turn, Dead-ball specialist, Fox in the box, Giving the goalkeeper the eyes, Head tennis, Hibs it, In a good moment, Leading the line The Maradona, Olimpico, Onion bag, Panenka, Rabona, Scorpion kick, Spursy, Tiki-taka, Where the kookaburra sleeps, Where the owl sleeps, Where the spiders sleep.DIVISION TWO Ball stays hit, Business end, Came down with snow on it, Cauldron atmosphere Coat is on a shoogly peg, Come back to haunt them, Easy tap-in, Daisycutter, First cab off the rank, Has that in his locker, High wide and not very handsome, Howler, One for the cameras, One for the purists, Played us off the park, Purple patch, Put their laces through it, Rolls Royce, Root and branch review, Row Z, Seats on the plane, Show across the bows, Stramash, Taking one for the team, That's great… (football), Thunderous strike.UNSORTED 2-0 is a dangerous score, After you Claude, All-Premier League affair, Aplomb, Bag/box of tricks, Brace, Brandished, Bread and butter, Breaking the deadlock, Bundled over the line, Champions elect / champions apparent, Clinical finish, Commentator's curse, Coupon buster, Cultured/Educated left foot, Denied by the woodwork, Draught excluder, Elimination line, Fellow countryman, Foot race, Formerly of this parish, Free hit, Goalkeepers' Union, Goalmouth scramble, Good touch for a big man, Honeymoon Period, In and around, In the shop window, Keeping ball under their spell, Keystone Cops defending, Languishing, Loitering with intent, Marching orders, Nestle in the bottom corner, Numbered derbies, Nutmeg, Opposite number, Park the bus, PK for penalty-kick, Postage stamp, Put it in the mixer, Rasping shot, Red wine not white wine, Relegation six-pointer, Rooted at the bottom, Route One, Roy of the Rovers stuff, Sending the goalkeeper the wrong way, Shooting boots, Sleeping giants, Slide rule pass, Small matter of, Spiders web, Stayed hit, Steepling, Stinging the palms, Stonewall penalty, Straight off the training ground, Taking one for the team, Team that likes to play football, Throw their cap on it, Thruppenny bit head / 50p head, Towering header, Two good feet, Turning into a basketball match, Turning into a cricket score, Usher/Shepherd the ball out of play, Walking a disciplinary tightrope, Wand of a left foot, We've got a cup tie on our hands, Winger in their pocket, Wrap foot around it, Your De Bruynes, your Gundogans etc.

L''Horoscope du Vendredi 14 Novembre

On today's 11.13.25 show  we talked about the new Trader Joes tote bags, Jess had an accurate prediction, new Doordash scam alert, Chis Evans rumored to be cheating on his wife, the flu is fluing this season, the Wicked For Good press tour has kicked off, Waymo is expanding, Timothy Chalamet has upset some people, a new Apple accessory, we have a marrylisa.com update and more!

Our guest this week is really into creepy crawlys and things with loads of legs. He's also mad into not cutting his grass. He's the biodiversity officer in Trinity College but he's also from Crumlin.. it's the wonderful Collie Ennis. Hosted on Acast. See acast.com/privacy for more information.

Scorpion Milk's Mat McNerny joins us today to discuss the most joyous of terrifying movies of the 80s, The Stuff. Mat's latest album is called 'Slime of the Times'  and I can not stop listening to it. So why not ask him to come onto a show about horror movies and combine my two passions. BOOM!

This week on the Toy Power Podcast; we welcome with open arms Mr. DaveyDamaged back into the studio, along with Trent! Yes! We are a Group of Five this round; and we start the show off with many many laughs! Dave updates us all around DvG before we get right into the Latest News! From HasLab Tron numbers to MOTU figures popping up on Australian shores; there is a lot to be on the pulse about! Loyal Subjects Wave 2 of their MASK line as well as Concept HeMan. Marvel Fans rejoice as there seems to be a never ending release of figures from various companies Plus a Lego set from a Different Galaxy, that has Frank very hyped! Thudercats, Mythic Legions, Godzilla & even Garfield are all covered as well. Then we take a trip via Radical Rewind - Back To The Future - with an absolutely awesome crowd, plus more DeLorean's than one can point a stick at! All this & a ton of laughs! Enjoy!!Support the show: http://patreon.com/toypowerpodcastSee omnystudio.com/listener for privacy information.

What if every ending was just the beginning of your next transformation? In this Big Crystal Energy deep dive, host Ashleigh Bodell explores the intense, mystical energy of Scorpio Season - a time of death, rebirth, and profound renewal. Drawing inspiration from the myth of Persephone, the Phoenix, and her own shadow-season experiences, Ashleigh reveals how to work with this energy through crystals, tarot, and ritual.You'll discover the most powerful stones for emotional healing and spiritual rebirth - like black obsidian, garnet, and malachite - plus journal prompts and intuitive practices to help you integrate your shadows and rise stronger than before.Whether you're crystal-curious, a mystic in metamorphosis, or just feeling Scorpio's cosmic pull, this episode invites you to dive deep, shed old skins, and reclaim your magic.Because transformation isn't a phase - it's your evolution.Key Moments: 15:29 "Scorpio: Transformation and Taboo"18:36 "Scorpio's Transformative Journey"22:12 Self-Reflection and Inner Healing26:18 Scorpio Season: Death as Renewal28:15 Scorpio's Transformative Stones.33:17 "Crystals for Self-Compassion"34:02 Scorpio Energy: Serpentine & Garnet38:53 "Scorpio Transformation Crystal Ritual"42:49 "Shadow Work Crystal Guide"44:49 Scorpio Influences: Fortune & Sagan48:40 Scorpio Season: Death & Rebirth50:53 "Power Lies in Your Shadows"Meet Ashleigh Bodell – your guide to the mystical and the magical on the Big Crystal Energy Podcast.By day, she's a dedicated orthopedic physician assistant, but by night, she dives deep into the metaphysical, exploring crystals, energy work, and the unseen forces that shape our world. From childhood fascinations with witches and faeries to a transformative rediscovery of crystals, Ashleigh's journey bridges science and spirituality, the practical and the mystical. A mom, a wife, and a seeker, she brings a relatable, no-fluff approach to exploring the “spooky and kooky” side of life. Through Big Crystal Energy, she creates a space where the magical and the mundane coexist—because we don't have to choose between our careers, families, and the call of the unknown.Tune in as she uncovers wisdom from crystal healers, spiritual coaches, and magic makers, inviting you to embrace your own big crystal energy.Connect Ashleigh : https://www.instagram.com/bigcrystalenergypodcast/https://www.instagram.com/mystical.mama.ashSend me any questions or comments you may have and I will answer them on upcoming podcast episodes!! Looking forward to hearing from you!Please message me with any questions or comments. bigcrystalenergypodcast @gmail.com

Losers have to eat a SCORPION??? Who greenlit this??See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Ryan Miller of Guster is the guest on this episode of That's How I Remember It. We recorded it live this past August at One Longfellow Square in Portland, Maine as part of Guster's very inspiring On the Ocean Festival. It was an amazing day and great to sit down with Ryan and talk about the last Guster record Ooh La La, The Scorpion's “Still Loving You”, high school bands, writing songs on new instruments, Matt Johnson and The The, working with new producers, Guster's college rep program and community building in this modern age. I came away from the weekend in awe of all Guster had put together and it was super great to speak with Ryan about the way they've approached things.

Today it's Lennons turn in the hot seat as we dive into the world of TV. Lennons takes us through the process of bringing his vision to light and what it means to put the best collectables Australia has to offer onto our screens. From Cards, jerseys, LEGO, Star Wars, Arcade machines, 90s goodness and more, there is something for everyone on this great Australian made show. Trent and Frank have each had a segment, but is there another Toy Power star in the wings? Whats in store for the future? You'll have to listen to find out. Watch Cards and Collectables right now on the 9Go app! To Find out more about Lennon & his TV Series: Cards And Collectables - be sure to check it out on Facebook, Instagram: @CardsAndCollectablesTV & on TV via channel 9 Now app - www.cardsandcollectables.com.au To Find out more from Matt & his business: Sports Card World - be sure to check them out on Facebook, Instagram: @SportsCardsWorldAdelaide & in person at their store in the heart of Adelaide City - Regent Arcade - Shop 5/101 Rundle Mall - Open 7days a week! www.sportscardworld.com.auSupport the show: http://patreon.com/toypowerpodcastSee omnystudio.com/listener for privacy information.

How does a short passage in Mark chapter 2 point to Jesus as Lord and God? And what might Jesus' healing of the paralytic say about the nature of the universe and our place within it? Can we trust Mark's account as real history? This is a short audio essay examines these questions in greater detail and hopefully provides us with some encouragement not to be discouraged in times when God seems silent. Thumbnail photo credit: NASA, ESA, CSA, and STScI, A. Pagan (STScI)). This is Pismis 24, a small star cluster in the constellation Scorpius, the Scorpion. The "small" mountain peak is over five light years in height - with a single light year being close to 6 trillion miles. That is a rather tall peak. The very One who came under our roof decorated this and all the other wondrous entities in the vaulted roof of the heavens. He who names and numbers all the stars also heals our broken hearts and binds up our wounds (Psalm 147). Podbean enables our podcast to be on Apple Podcasts and other major podcast platforms.  To support Good Heavens! on Podbean as a patron, you can use the Podbean app, or go to https://patron.podbean.com/goodheavens.  This goes to Wayne Spencer. If you would like to give to the ministry of Watchman Fellowship or to Daniel Ray, you can donate at https://www.watchman.org/daniel. Donations to Watchman are tax deductible.

On today's new episode the guys talk Beneath the Trees Where Nobody Sees Beneath the Trees Where Nobody Sees is an original graphic novel written and drawn by Patrick Horvath and published by IDW about Samantha Strong, a serial killer who is also a beloved member of her small, anthropomorphic animal town. When a rival killer begins murdering locals, Samantha must hunt them down to protect her secret and prevent the town from self-destructing. The story is known for its dark, violent plot juxtaposed with a cute, Richard Scarry-style art style. But first did Cody make sure the military wasn't at New York Comic Con? Was this one of the best books of 2024? Does this comic have Dexter vibes? What do we call watching movies with William Hurt? Does this book take place in the 80s? Is Cody aging like fine wine? How does Samantha Strong feel about her community? Did we guess the killer? What's going on in the next volume of this series? How cold is Samantha? Is Good Luck Chuck the Casablanca of our generation? What is scary and creepy about the first murder that draws you in? What does Anthony tell us about DC KO? What other crossovers are happening in comics recently? Who would win between Samantha Strong and Scorpion from Mortal Kombat? Who would we be in this comic? Did Satan tempt Eve to smoke from an apple? Find out the answer to these and more on the newest issue of Comics and Chronic!Check out the Kickstarter pre-launch page for Superguy issue #2 ⁠⁠⁠⁠https://www.kickstarter.com/projects/mrtonynacho/superguy-2-my-date-with-the-presidents-daughter?ref=creator_tab⁠New episodes every THURSDAYFollow us on social media! Bluesky // Instagram // Twitter // TikTok :⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@comicsnchronic⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.youtube.com/channel/UC45vP6pBHZk9rZi_2X3VkzQ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠E-mail: comicsnchronicpodcast@gmail.comCodyInstagram // Bluesky:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@codycannoncomedy⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter: @Cody_CannonTikTok: @codywalakacannonJakeInstagram // Bluesky:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@jakefhaha⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠AnthonyBluesky // Instagram // Threads // Twitter // TikTok:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@mrtonynacho⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

“Whether or not money comes out of this is yet to be seen. The main thing is—does it help people? Is it spreading a good message? That's ultimately why I'm doing this.” — Heather Snodgrass Actor, author, and debut novelist Heather Snodgrass joins me to talk about her first book, A Love Letter to Reading, a story that blends heart-pounding suspense with deep emotional reflection. A graduate of the American Academy of Dramatic Arts, Heather shares how her journey from acting to screenwriting to novel writing taught her to embrace creative detours and stay rooted in gratitude. Together, we explore her unconventional protagonist, Scorpion—a pediatric oncologist who moonlights as an assassin—and how writing her story became a form of self-discovery and healing.  Key Takeaways: Transformation through art: Heather's path from acting to writing shows how creative callings evolve—and how storytelling finds new forms when one door closes. A character unlike any other: Her protagonist, Scorpion, is both assassin and healer—an embodiment of duality, morality, and redemption that challenges genre conventions. Writing as therapy: Heather used self-care rituals like gardening and mindfulness to process heavy emotional material, proving that writers must protect their own well-being during intense creative work. The publishing learning curve: She opted for a hybrid publishing model to get her story into readers' hands sooner, highlighting the importance of understanding all paths to publication. Feedback with perspective: Heather learned to balance taking constructive criticism seriously while still trusting her creative instincts—a valuable mindset for any creator. Purpose over profit: Her biggest takeaway—focus on impact, not income. Writing should be about helping others and spreading light, even if the financial rewards come later. Finding inspiration: Movies, music, and other art forms often reignite her creativity—reminding us that to get back into flow, sometimes you must step away from your own work. Buy A Love Letter to Reading Amazon: https://amzn.to/4gYqHkB Bookshop: https://bookshop.org/a/54587/9798894273396 Connect with Heather Website: https://www.authorheathersnodgrass.com/ Instagram: https://www.instagram.com/melted_heathbar/ TikTok: https://www.tiktok.com/@heathersnodgras5 Connect with Mike Website: https://uncorkingastory.com/ Youtube: https://www.youtube.com/channel/UCSvS4fuG3L1JMZeOyHvfk_g Instagram: https://www.instagram.com/uncorkingastory/ TikTok: https://www.tiktok.com/@uncorkingastory Twitter: https://twitter.com/uncorkingastory Facebook: https://www.facebook.com/uncorkingastory LinkedIn: https://www.linkedin.com/company/uncorking-a-story/ If you liked this episode, please share it with a friend. If you have not done so already, please rate and review Uncorking a Story on Apple Podcasts, or wherever you get your podcasts. #UncorkingAStory #HeatherSnodgrass #ALoveLetterToReading #AuthorInterview #CreativeJourney #HybridPublishing #WritingCommunity #AmWriting #BookLaunch #FemaleAuthors #InspirationForWriters Learn more about your ad choices. Visit megaphone.fm/adchoices

“I didn't dig too deep because I didn't want to see pictures of scorpions!”If this episode was just about Serket, it would be 15 minutes long. So, she's being joined in this episode by another goddess! Can you guess who? (DJ sure can!)Other topics include DJ's delivering some excellent wordplay, Darien's deep fear of even digital scorpions, divine support in the marriage bed, DJ guessing Darien's attempt at a twist, a shout-out for Shucked, Darien struggling to pronounce the word “sphere,” and giving the oldest goddess of the Egyptian Pantheon her due.Content Warning: This episode contains mentions of and conversations about scorpions, animal bites, and death by venom.Spoilers for The Court of the Dead and SMITEEnjoy over 100 bonus episodes available NOW on Patreon! https://www.patreon.com/musesofmythologyAbout UsMuses of Mythology was created and co-hosted by Darien and DJ Smartt.Our music is Athens Festival by Martin Haene. Our cover art is by Ranpakoka. Find him on Instagram @Ranpakoka  Love the podcast? Support us on Patreon and get instant access to bloopers, outtakes, and bonus episodes! Patreon.com/musesofmythologyGet you hands on podcast merch at Musesofmythology.com/merchFind us @MusesOfMyth on Instagram. Find all of our episodes and episode transcripts at MusesOfMythology.com----------------------- Support the showNo portion of this episode may be used for AI training purposes or to create derivative works without express written permission from the creators and co-hosts Darien Smartt or Davis Smartt.